Abstract
Objective To infer Covid-19 incubation time distribution from a large sample.
Method Based on individual case data published online by 21 cities of China, we investigated a total of 136 COVID-19 patients who traveled to Hubei from 21 cities of China between January 5 and January 31, 2020, remained there for 48 hours or less, and returned to these cities with onset of symptoms between January 10 and February 6, 2020. Among these patients, 110 were found to be aged 15 – 64, 22 aged 65 – 86, and 4 aged under 15.
Findings The differential incubation time histogram of the two age groups 15 – 64 and 65 – 86 are adequately fitted by the log normal model. For the 15 - 64 age group, the median incubation time of 
days (uncertainties are 95 −0.90 % CL) is broadly consistent with previous literature. For the 65-86 age group, the median is 
days is statistically significantly longer. Moreover, for −2.0 this group, the 95 % confidence contour indicates the data cannot constrain the upper bound of the log normal parameters µ, σ by failing to close there; this is because the sample has a maximum incubation time of 17 days, beyond which we ran out of data even though the histogram has not yet peaked. Thus there is the potential of a much longer incubation time for the 65-86 age group than 10 – 14 days. Only a much larger sample can settle this.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding support of this research.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
